Advanced

Challenges to medications development in treating alcohol dependence: An international perspective - Summary of a symposium held at the ESBRA Congress, Prague, 13 September 2003

Littleton, JM; De Witte, P; Litten, R; Gessa, GL; Spanagel, R; Kranzler, H; Lehert, P; Johnson, B; Saunders, J and Berglund, Mats LU , et al. (2004) In Alcohol and Alcoholism 39(4). p.271-275
Abstract
Few medications for treating alcohol dependence exist. Greater partnership is needed between academia and the pharmaceutical industry to develop, licence and market efficacious medications for treating alcohol dependence. Methodologies that span the divide between preclinical and large-scale clinical studies need to be developed in order to provide sufficient information on safety, toleration, drug-interaction profile and efficacy, with which to guide development decisions. Due to the heterogeneous nature of alcohol dependence, the effort of developing an efficacious medication is likely to be enhanced by clearer choices about the characteristics of the population. Careful consideration of potential mechanism of action of the putative... (More)
Few medications for treating alcohol dependence exist. Greater partnership is needed between academia and the pharmaceutical industry to develop, licence and market efficacious medications for treating alcohol dependence. Methodologies that span the divide between preclinical and large-scale clinical studies need to be developed in order to provide sufficient information on safety, toleration, drug-interaction profile and efficacy, with which to guide development decisions. Due to the heterogeneous nature of alcohol dependence, the effort of developing an efficacious medication is likely to be enhanced by clearer choices about the characteristics of the population. Careful consideration of potential mechanism of action of the putative therapeutic medication should enable the appropriate choice of drinking endpoint. The pharmaceutical industry in collaboration with academia might need to develop new approaches to determining appropriate treatment endpoints with regulatory bodies. The investment risk to industry should be appraised not only in terms of the rather poor results of previous marketing efforts but with a view to the opportunity to penetrate a potentially enormous and largely untapped market. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Alcohol and Alcoholism
volume
39
issue
4
pages
271 - 275
publisher
Oxford University Press
external identifiers
  • wos:000222270300001
  • scopus:3242762314
ISSN
1464-3502
DOI
10.1093/alcalc/agh067
language
English
LU publication?
yes
id
247715bd-96c2-4c24-9b6d-cd320470e292 (old id 273623)
date added to LUP
2007-10-24 20:03:41
date last changed
2017-01-01 04:26:45
@article{247715bd-96c2-4c24-9b6d-cd320470e292,
  abstract     = {Few medications for treating alcohol dependence exist. Greater partnership is needed between academia and the pharmaceutical industry to develop, licence and market efficacious medications for treating alcohol dependence. Methodologies that span the divide between preclinical and large-scale clinical studies need to be developed in order to provide sufficient information on safety, toleration, drug-interaction profile and efficacy, with which to guide development decisions. Due to the heterogeneous nature of alcohol dependence, the effort of developing an efficacious medication is likely to be enhanced by clearer choices about the characteristics of the population. Careful consideration of potential mechanism of action of the putative therapeutic medication should enable the appropriate choice of drinking endpoint. The pharmaceutical industry in collaboration with academia might need to develop new approaches to determining appropriate treatment endpoints with regulatory bodies. The investment risk to industry should be appraised not only in terms of the rather poor results of previous marketing efforts but with a view to the opportunity to penetrate a potentially enormous and largely untapped market.},
  author       = {Littleton, JM and De Witte, P and Litten, R and Gessa, GL and Spanagel, R and Kranzler, H and Lehert, P and Johnson, B and Saunders, J and Berglund, Mats and Harris, A and Anton, R and Mann, K},
  issn         = {1464-3502},
  language     = {eng},
  number       = {4},
  pages        = {271--275},
  publisher    = {Oxford University Press},
  series       = {Alcohol and Alcoholism},
  title        = {Challenges to medications development in treating alcohol dependence: An international perspective - Summary of a symposium held at the ESBRA Congress, Prague, 13 September 2003},
  url          = {http://dx.doi.org/10.1093/alcalc/agh067},
  volume       = {39},
  year         = {2004},
}